ACKR3 and cancer: NOX-A12, because of its ability to block SDF-1 activity on both of its receptors, CXCR4 and CXCR7, provides additional benefit over a targeted CXCR4 receptor inhibitor because of its dual influence on CXCR7, which affects proliferation, migration, and metastasis of some cancers [43].